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Therapeutic monoclonal antibodies have become molecules of choice to treat autoim-
mune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific 
antibodies that target more than one antigen or epitope on a target cell or recruit effector 
cells (T cell, natural killer cell, or macrophage cell) toward target cells have shown great 
potential to maximize the benefits of antibody therapy. In the past decade, many novel 
concepts to generate bispecific and multispecific antibodies have evolved successfully 
into a range of formats from full bispecific immunoglobulin gammas to antibody fragments. 
Impressively, antibody fragments such as bispecific T-cell engager, bispecific killer cell 
engager, trispecific killer cell engager, tandem diabody, and dual-affinity-retargeting are 
showing exciting results in terms of recruiting and activating self-immune effector cells 
to target and lyse tumor cells. Promisingly, crystallizable fragment (Fc) antigen-binding 
fragment and monomeric antibody or half antibody may be particularly advantageous to 
target solid tumors owing to their small size and thus good tissue penetration potential 
while, on the other hand, keeping Fc-related effector functions such as antibody-de-
pendent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent 
cell-mediated phagocytosis, and extended serum half-life via interaction with neonatal 
Fc receptor. This review, therefore, focuses on the progress of Fc engineering in gen-
erating bispecific molecules and on the use of small antibody fragment as scaffolds for 
therapeutic development.
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iNTRODUCTiON
Since approval of the first therapeutic monoclonal antibody (mAb) muromonab-CD3 by the United 
States Food and Drug Administration for treatment of organ transplant-associated acute rejections 
in 1992, a total of 62 mAbs have been approved by the USFDA for clinical use as of May 2016 
(1, 2). Therefore, the USFDA has approved an average of two to three mAbs each year over the 
last 25 years. Surprisingly, in 2015, a total of 10 mAbs were approved (2). Clearly, the demand for 
antibody molecules and global sales have been rising rapidly.
Most therapeutic mAbs are complete immunoglobulin gamma (IgG) molecules which consist 
of two heavy and two light chains that fold into a complex quaternary Y-shaped structure (1). The 
FiGURe 1 | Formats of bispecific antibodies and scaffolds described in the literature. (A) Bispecific quadroma generated by somatic fusion of two 
hybridomas, (B–J) bispecific formats developed by using knobs-in-holes (KiH) Fc heterodimerization strategy, (K) bispecific IgG1 developed by controlled Fab-arm 
exchange, (L) bispecific Fc-fusion constructs developed by electrostatic optimization, (M–O) bispecific formats developed by strand exchange, insertion of cleavage 
motif and expressing two light chains with single heavy chain, and (P–w) novel bispecifc or multi-specific scaffolds. Abbreviations: OAscFab-IgG, one-arm 
single-chain Fab-immunoglobulin gamma (IgG); dsFv-IgG, disulfide stabilized Fv-IgG; cFAE-IgG1, controlled Fab-arm exchanged-IgG1; scFv-Fc, charged pair single-
chain Fv-Fc fusion; SEEDbody, strand-exchange engineered domain body; LUZ-Y, two-arm leucine zipper heterodimeric monoclonal antibodies; (κλ-body, kappa 
lambda body; BiTEs, bispecific T-cell engagers; BiKEs/TriKEs, bispecific/trispecific killer cell engagers; DART, dual-affinity retargeting molecules; mFc, monomeric 
Fc; Fcab, Fc antigen binding. Color codes are as follows: heterodimeric CH domains are shown in black and white; cognate light chains are shown in green and 
orange; the antigen-binding domains [VH (black/white), VL (green/orange), and VH–VL (paired white–orange/black–green)] are shown as indented bubble; additional 
specificity in trispecific molecules is shown by red/blue scFv or VH–VL pair (G,i,U); light chains of κλ-body (O) are shown in light and dark green; red bulge at 
CH3–CH3 interface depicts knobs-in-holes motif; curved arrows indicate cross-matched domains; interchain linkers are shown as red lines; interchain disulphide 
bonds are shown as black lines; engineered disulfide bonds are shown as yellow lines; red stripes depict exchanged sequences; black asterisks indicate site of 
mutations favoring heterodimerization; orange asterisks indicate protein A ablation mutation (J). +/− represents charged pair mutations; lightning bolt indicates 
cleavable peptide linkers.
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two arms of the Y-shaped molecule form the antigen-binding 
domains called antigen-binding fragment (Fab) regions, and the 
stalk forms the crystallizable fragment (Fc) region. Native IgG 
molecules can be digested by papain protease into separate F(ab)2 
dimers and Fc domains (3). Fab arms are responsible for antigen 
binding and have been extensively engineered for developing 
highly specific and synthetic antibodies against numerous targets 
(4). The Fc region bears recognition motifs for binding innate 
immune receptors [Fcγ receptors (FcγRs), C1q, and neonatal Fc 
receptor (FcRn)] on an effector cell and thus is responsible for 
mediating immune effector functions and in  vivo IgG stability 
(5–11). This part has been a prime molecular engineering target 
for either enhancing or inhibiting the immune response includ-
ing antibody-dependent cellular cytotoxicity (ADCC), comple-
ment-dependent cytotoxicity (CDC), and antibody-dependent 
cell-mediated phagocytosis (ADCP) (9, 12–14). Besides the Fab 
domain, antigen-binding character has also been engineered into 
the Fc, CH2, and CH3 domains (15, 16). Such novel fragments 
have demonstrated therapeutic-like profiles in early studies and 
remain attractive ventures.
Antibody molecules can be made more efficient by engineer-
ing additional specificities so that multiple antigens or epitopes 
present on a cell can be targeted (17, 18). Extensive academic 
and industrial research in the past decade focused on develop-
ing bispecific Abs and Igs (bsAbs and bsIgs) and multispecific 
antibodies (e.g., TriMabs) (17–20).
Initially, bsAbs were generated by a quadroma technology, 
which required the somatic fusion of two hybridomas harboring 
different specificities (21, 22). This led to the foundation of bispe-
cific antibody production for simultaneous targeting of two dif-
ferent antigens or epitopes on a cell (Figure 1A). However, these 
molecules suffered from low production yields, heterogeneity, 
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and human anti-mouse antibody (HAMA) response and there-
fore a decreased efficacy in patients (23). Nevertheless, one such 
bsAb EpCAM ×  CD3 (triomab; catumaxomab) was approved 
by the European Medicines Agency in 2009 for the treatment of 
patients with epithelial cancer-associated malignant ascites (24). 
Two additional bsAbs produced using the quadroma method, 
HER2 × CD3 (triomab; ertumaxomab) and CD20 × CD3 (trio-
mab; FBTA05), are being evaluated in clinical trials for cancer 
treatment (25, 26).
Later, bsAb construction primarily relied on Fc heterodi-
merization by creating “knobs-in-holes” (KiH) mutations in 
the CH3 domain, which is prerequisite to assemble two half 
antibodies (common Fc heterodimer and unique VH–CH and 
VL–CL domains) (27–29). However, a major bottleneck in this 
strategy has been the incorrect pairing of light–heavy chains. 
Consequently, newer strategies based on KiH and other platforms 
have been developed to circumvent faulty heavy and light chain 
pairing.
Small antibody fragments like nanobodies from llama and 
camel immune systems (30–33), single human domain antibod-
ies (34–37), and single-chain variable fragments (scFvs) (38, 39) 
can be used to impart bispecificity or multispecificity to antibody 
molecules (18). Moreover, small non-immunoglobulin fragments 
like monoclonal lamprey antibodies (lambodies) (40), affibodies 
(41), and DNA/RNA aptamers (42, 43) can be fused with the anti-
body Fc fragment (homodimerization or heterodimerization) 
to have antibody-like properties such as Fc-associated effector 
functions (ADCC, CDC, and ADCP), extended pharmacokinet-
ics and bispecificity (44, 45).
In this review, we describe recent advances in the therapeutic 
potential of bispecific molecules and small Ab fragments as 
novel scaffolds. We summarize the key breakthroughs achieved 
by employing and optimizing various strategies. Representative 
design, expression, purification, and purity of final bispecific mol-
ecules are summarized (see Table 1). Some bispecific antibodies 
and antibody fragments currently under clinical evaluation are 
listed (see Table 2), and graphical models of bispecific molecules 
under development are presented (see Figure 1).
STRUCTURAL OPTiMiZATiON
The KiH (Figure  1B) concept was first proposed by Ridgway 
et al. (29) to develop Fc heterodimers. It allows the generation 
of complementary interacting interfaces by manipulating key 
amino acid residues that participate in the Fc dimeric interac-
tion. Amino acids with small side chain are replaced by ones with 
larger side chains, thereby creating a knob or protrusion in one 
chain and vice versa to create a hole or socket in the partner chain. 
Traditionally, a T366Y mutation in one CH3 domain has been 
used to create a knob while an Y407T mutation in the other CH3 
domain (hereafter denoted as Y407′T) gives rise to a hole (29). 
Such mutations establish intermolecular interactions and promote 
the heterodimer formation due to knob/hole pairing and bring 
about the association of two different Fab regions to give rise to a 
monovalent bsIg. It was also found that complementing existing 
knob/hole mutations with F405A and T394′W on the knob and 
hole side, respectively, yielded 92% molecules as heterodimers 
(29). In an effort to further improve and stabilize the KiH model, 
a phage-displayed library of CH3 (T366W) knob domain and 
CH3 (randomized at 366′, 368′ and 407′) hole domain was cre-
ated by fusing FLAG-tagged CH3-hole to the N-terminal region 
of the gene-III minor coat protein of M13 bacteriophage (27). 
The heterodimers were selected by an anti-FLAG antibody and 
were found to be completely diverse from parent T366W–Y407′A 
clone. Phage display optimized variants existed preferably as 
heterodimers and exhibited greater stabilities (27).
The KiH concept suffered from mispairing of heavy and 
light chains in the heterodimers. Merchant et al. (28) suggested 
using identical light chains for both Fab domains, which can be 
further stabilized by engineered disulfide bonds (Figure  1C). 
They employed a scFv phage-displayed library with restricted 
light chain usage to identify antibodies recognizing c-MPL and 
HER3 using common light chains and developed a bispecific 
c-MPL × HER3 antibody with approximately 95% heterodimer 
recovery (28).
However, it is not always possible to use a common light chain 
for developing bispecific molecules because antigen recognition 
can critically rely on the partner light chain (73, 74). To circum-
vent the existing light chain mispairing in bsIgs, a methodology 
termed as “CrossMab” (47) was developed and combined with 
the KiH technology. In principle, “CrossMab” is achieved by 
the exchange between heavy and light chains of the Fab portion 
of one partner in order to generate formats of “CrossMab Fab” 
(Figure  1D), “CrossMab VH–VL” (Figure  1E), or “CrossMab 
CH1–CL” (Figure  1F) (47). Such bispecific formats clearly 
reduced the heavy–light chain mispairing, allowed simultaneous 
recognition of the two antigens (VEGF-A and Ang2), retained 
the affinity and stability profiles of the parent antibodies and 
exhibited antiangiogenic and antitumor activity in vivo (47).
Similarly, trispecific antibodies “TriMabs” (Figure  1G) 
were developed and combined with the KiH technology using 
N-terminal single-chain Fab (scFab) and C-terminal scFv fusions 
of Fc region, which avoids the light chain mispairing. The concept 
was demonstrated by using four specificities (EGFR, IGFR, cMET, 
and HER3) incorporated into three structural formats (19). 
TriMabs 1 and 2 engage their respective antigen in a monovalent 
manner while TriMab 3 binds HER3 in a bivalent fashion. These 
molecules retained their ability to bind individual antigens and 
shared kinetic properties with their parent molecules. Besides, 
the TriMabs were also shown to simultaneously recognize their 
respective antigens when immobilized on a chip or expressed on 
human pancreatic adenocarcinoma cells (BXPC-3) and inhibited 
receptor signaling and tumor growth (19).
An scFab heterodimeric bsIg format (OAscFab-IgG) 
(Figure  1H) with anti-IGF1R and anti-EGFR specificities has 
also been described to prevent faulty chain pairing (48). The light 
chains in the scFab format were attached to the N-terminus of the 
heavy chain through a 32-residue linker, and heterodimer forma-
tion was achieved by KiH mutations. This strategy allowed the 
recovery of 99% pure heterodimers, which exhibited comparative 
antigen-binding affinity to the parent antibodies (48).
Further, a conditional functionality was engineered in a bispe-
cific molecule which relied on proteolytic cleavage to generate 
functional binders. The VH and VL domains incorporating C44 
TABLe 1 | Strategies to promote bispecificity by heterodimer formation.
Strategy/
format
Mutation Target Bispecificity  
analysis/yield (%)
Protein expression/purification/
yield (g/L)
Remarks Reference
Quadroma NA EpCAM × CD3, HER3 × CD3, 
CD20 × CD3
Ion-exchange 
chromatography and 
SEC/12.5%
Hybridoma/protein A Associated human 
anti-mouse antibody 
response
(26, 46)
Knobs-in-holes T366W/T366Y (knobs) and T366S/L368A/
T394W/F405A/Y407V(T) (holes)
CD3 × CD4, c-MPL × HER3, 
VEGF-A × Ang2, CD20 × hL243γ1, 
EGFR × IGF1R, HER3 × cMET, 
CD3 × EpCAM, CD3 × HER2, 
EGFR × HER2, CD4 × CD70, 
MET × EGFR
Electroblotting, SLD, SEC, 
MS-TOF (73–100%)
HEK293, Escherichia coli, and cell-free 
expression system/protein A, DEAE, 
and Mab Select Sure/0.004–1.0 g/L
Faulty light and heavy 
chain pairing
(19, 27–29, 
47–53)
Biochemical 
optimization
S364H/F405A (CH3A) andY349T/T394F 
(CH3B)
CD16 × HER2 and CD3 × HER2 HPLC/SEC (89%) HEK293F/protein A, nickel affinity 
chromatography
(54)
Biochemical 
optimization
L368E/K409R (CH3), R221E/R228E 
(IgG1-hinge), and R223E/R225E/R228E 
(IgG2-hinge)
CD3 × CD20, EGFR × ErbB2 Ion-exchange 
chromatography and LCMS 
(65–100%)
HEK293/protein A/in vitro cell-free 
assembly
Cognate chain pairing (55)
Biochemical 
optimization
P228S (IgG1-hinge) and F405L/K409R (CH3) CD20 × EGFR ESI-MS (95.7%) HEK293/protein A/SEC/473.4 g/L High yield and efficiency (56)
Biochemical 
optimization
H435R and Y436F (IgG1-CH3) CD20 × CD3 SEC (100%) Stable CHO-K1/protein A/0.2–0.3 g/L Cognate chain pairing (57, 58)
Biochemical 
optimization
S354C (CH3A), Y394C (CH3B), F126C 
(CH1), S121C (LC), C44 (VH), and C100 (VL)
EGFR × IGF1R, CD20 × hL243γ1, 
HER3 × cMET
MS-TOF, SEC (73%) HEK293/protein A/0.004–0.03 g/L Prevent homodimer 
formation
(49, 52, 53)
Biochemical 
optimization
F241R, F243S, F241S, F243R (CH2) and 
C226S, C229S (hinge)
NA MS-TOF (90%) E. coli/protein A Avoid covalent bonding 
of heterodimers
(50)
Electrostatic 
optimization
K409D (CH3A), D399R (CH3B), K409E 
(CH3A), D399K (CH3B), and K409E (CH3A), 
D399R (CH3B)
CD3 × TARTK LC/MS (98%) HEK293/Select Sure column and SEC Prevent homodimer 
formation
(59)
Electrostatic 
optimization
K409W, K360E, K370E (CH3A) and D399V, 
F405T, Q347R, E357N, S364B (CH3B)
VEGFR-2 × MET SEC (80–90%) HEK293/protein A Prevent homodimer 
formation
(60, 61)
Electrostatic 
optimization
Q39K, Q105K (VH), S183D (CH1), Q38D 
(VL), S176D (CL), K392D, K409D (CH3A), 
and E356K, D399K (CH3B)
HER2 × EGFR SEC (100%) Stable CHO/protein A/0.2–0.3 g/L Cognate chain pairing (57)
Electrostatic 
optimization
T350V, L351Y, F405A, Y407V (CH3A) and 
T350V, T366L, K393L, T394W (CH3B)
HER2 × ErbB2 SEC (95%) CHO/protein A/0.25 g/L Improved biophysical 
properties
(62)
κλ-body NA CD19 × CD47, CD47 × EpCAM Isoelectric focusing/41.5% PEAK cells/protein A, CaptureSelect 
immunoglobulin gamma (IgG)-CH1, 
KappaSelect, and LambdaFabSelect 
affinity chromatography/1.5 g/L
Exploits variable light 
chains for generating 
bispecifics
(63)
(Continued)
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or C100 mutations, respectively, were attached to the C-termini of 
the Fc region in knob and hole mutant, respectively, via a flexible 
linker. The VH C44 and VL C100 generate a disulfide stabilized 
Fv (Figure  1I), bypassing the requirement of a VH–VL linker 
to promote heterodimer formation in such an arrangement (49). 
Here, the C-terminal attachment does not affect off-rate and 
instead relieves steric hindrance after proteolytic cleavage. This 
methodology can be applied to express toxic products in an inac-
tive state in a cell which can be activated later during the process-
ing steps by proteolytic cleavage (49). This design incorporated 
a proteolytic motif for Pre-Scission within the peptide linker 
on one of the partner chains. The recognition motif for other 
proteolytic systems like furin, matrix metalloproteinase-2/9, or 
urinary plasminogen activator can also be engineered for varying 
applications (49).
Next, a structure-guided approach was used to generate bsIg 
by separately expressing monomeric IgG (harboring KiH muta-
tions) in Escherichia coli. Equimolar amounts of two monomeric 
IgGs, when mixed together at a basic pH, resulted mostly in heter-
odimeric IgGs (50). These constructs also incorporated mutations 
in CH2 domain residues (F241R/F243S or F241S/F243R) which 
remain solvent exposed in aglycosylated IgG molecules and the 
hinge region (C226S/C229S) to avoid covalent association of 
knob/knob or hole/hole monomers (50).
Recently, Xu et al. (51) utilized a cell-free expression system 
to generate bsIg based on KiH format. They used anti-CD3, 
anti-EpCAM, and anti-HER2 antibodies to generate eight bsIgs 
in four different KiH scaffolds. Among these scaffolds, scFv-KiH 
and scFv-KiHr (reverse) exhibited superior yields. Moreover, this 
system allowed optimal heterodimer expression by using equi-
molar plasmid ratios with an insignificant amount of free chains 
(51). The Fc fragments with a hole were found to be more stable 
than Fc-knob, and it was suggested to fuse difficult-to-express 
proteins to Fc-hole for high-level of expression (51).
Using the KiH platform, Mazor et  al. (52) introduced two 
cysteine pairs in the CH1–CL interface of one of the Fab arm 
to create disulfide bonds for correct light chain pairing. Almost 
100% monovalent bsIg was recovered from variant with 
CH1 (F126C) and CL (S121C) mutations. These mutations 
were applied to construct EGFR  ×  HER2 and CD4  ×  CD70 
“DuetMabs” (Figure  1J) (52) and were shown to be devoid of 
any free chains or fragments and had a molecular mass similar to 
native IgG. The thermal stabilities of EGFR × HER2 (Tm = 55°C) 
and CD4 ×  CD70 (Tm =  58°C) antibodies were comparable to 
the parental antibodies. DuetMabs could simultaneously engage 
their targets and as a result CD4 × CD70 DuetMab preferentially 
recognized CD4+CD70+ T cells over CD4+CD70− or CD4−CD70+ 
T cells. Similarly, the EGFR ×  HER2 molecule shared binding 
kinetics with parental antibodies and also exhibited normal bind-
ing to FcγRs, C1q, and FcRn (52).
Based on multistate designs involving molecular modeling, 
X-ray crystallography validation, and rounds of iteration, Lewis 
and coworkers (75) identified several favorable mutants across the 
interface of VH–VL and CH1–CL for formation of an orthogonal 
Fab interface. In combination with previously reported Fc muta-
tions in favor of the Fc heterodimerization (59), five bsIgs were 
correctly assembled from six parental mAbs with an average of 
TABLe 2 | Bispecific antibody candidates under clinical evaluation.
Format Strategy Target Clinical development phase Disease Company
bsAb/bsAb Fragment
Catumaxomab Triomab Quadroma EpCAM × CD3 Approved by European Medicines Agency EpCAM+ tumor; malignant ascites Neovii Biotech
Phase-2 (NCT00189345) Platinum refractory epithelial ovarian 
carcinoma
AGO Study Group
Phase-2 (NCT01504256) Gastric adenocarcinoma AIO-Studien-gGmbH
Phase-2 (NCT01246440) Ovarian cancer Grupo Espanol de Investigacion 
en Cancer de Ovario
Ertumaxomab Triomab Quadroma HER2 × CD3 Phase-1/2 (NCT01569412) Her2/Neu+ advanced solid tumor Krankenhaus Nordwest
Phase-2 (NCT00351858)
Phase-2 (NCT00452140) Advanced metastatic breast cancer Neovii Biotech
Phase-2 (NCT00522457)
FBTA05 Triomab Quadroma CD20 × CD3 Phase-1/2 (NCT01138579) CLL Technische Universitat Munchen
RO695688 Crossmab Knobs-in-
holes (KiH)
CEA × CD3 Phase-1 (NCT02324257) Advanced metastatic CEA+ solid tumors Hoffmann-La Roche
RO5520985 Crossmab KiH Ang2 × VEGFA Phase-1 (NCT01688206) Advanced or metastatic solid tumors Hoffmann-LA Roche
RO5520985 Crossmab KiH Ang2 × VEGFA Phase-2 (NCT01688206) Advanced or metastatic solid tumors Hoffmann-La Roche
Phase-2 (NCT02484690) AMD Hoffmann-La Roche
RG7813 scFv-IgG NA CEA × IL-2 Phase-1 (NCT02004106) Advanced metastatic CEA+ solid tumors
MM-141 scFv-IgG NA IGF × HER3 Phase-1 (NCT01733004) Advanced solid tumor Merrimack Pharmaceuticals
Phase-2 (NCT02399137) Metastatic pancreatic cancer Merrimack Pharmaceuticals
MOR209/ES414 scFv-IgG NA PSMA × CD3 Phase-1 (NCT02262910) Metastatic prostate cancer Aptevo Therapeutics
LY3164530 Ortho-Fab IgG Structural 
optimization
MET × EGFR Phase-1 (NCT02221882) Metastatic neoplasm Eli Lilly and Company
ALX-0061 Nanobody NA IL-6R × HSA Phase-2 (NCT01284569) Rheumatoid arthritis Ablynx
ATN-103 Nanobody NA TNF × HSA Phase-2 (NCT01063803) Rheumatoid arthritis Ablynx
Blinatumomab Bispecific T-cell 
engager BiTE
NA CD3 × CD19 Approved by Food and Drug Administration ALL Amgen GmbH
Phase-1 (NCT00274742) Relapsed NHL Amgen GmbH
Phase-2 (NCT01207388) Residual ALL Amgen GmbH
Phase-2 (NCT01209286) Relapsed/refractory ALL Amgen GmbH
Phase-1 (NCT02568553) Relapsed NHL National Cancer Institute
Phase-2 (NCT02143414) ALL National Cancer Institute
Phase-3 (NCT02003222) BCR-ABL−/− B-cell lineage ALL National Cancer Institute
Solitomab BiTE NA CD3 × EpCAM Phase-1 (NCT00635596) Advanced solid tumors Amgen GmbH
AMG330 BiTE NA CD33 × CD3 Phase-1 (NCT02520427) AML Amgen GmbH
(Continued)
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93% success rate (75). More recently, Leaver-Fay and coworkers 
(76) furthered the multistate design strategy by construction of a 
negative state pool across the CH3 interface via protein docking 
and sequence design. Several novel mutants were discovered to 
favor the formation of Fc heterodimerization with a purity of 
more than 90% (76). In combination with the orthogonal Fab 
interface, four fully bsIgs could be correctly formed with an aver-
age success rate of more than 93% in one-step process (76).
CH1–CK heterodimeric scaffold can be used to build bispe-
cific molecules (77, 78). However, it is known that the CH1–CK 
pair alone is not strong enough to form a stable heterodimer 
and CH1–CK pair requires cooperation from VH–VL pair for a 
stable heterodimer assembly (79, 80). To improve the CH1–CK 
heterodimerization in the absence of VH–VL pair cooperation, 
Chen et al. employed structure-based design in combination with 
phage display directed evolution (81). They identified that a S66V 
mutation in the CH1 domain together with a S69L in the CK 
domain can stabilize CH1–CK heterodimerization and increase 
the in vivo serum half-life of a previously described CD4-antibody 
fusion protein (4Dm2m), which targets the CD4-induced (CD4i) 
coreceptor binding site of the human immunodeficiency virus 
(HIV) 1 envelope glycoprotein 120 (81–84). It seems that this 
CH1–CK stabilization may increase the overall stability of 
4Dm2m and thus improve its pharmacokinetics. Moreover, the 
strengthened CH1–CK heterodimerization may pave the way for 
construction of bispecific molecules based on this scaffold (81).
BiOCHeMiCAL OPTiMiZATiON
A structure and sequence guided approach identified low energy 
amino acid pairs in the CH3 domain, which could promote 
heterodimer formation (54). These mutations were engineered 
into the design of a new library, which increased the heterodimer 
yield up to 89%. The strategy was applied to either Fc/single-chain 
Fv-Fc fusion (scFv-Fc) or scFv-Fc formats utilizing two differ-
ent CH3 domains favoring heterodimer formation to generate 
CD16 × HER2 bispecific, which exhibited improved antitumor 
attributes against the breast cancer cell line SKBr3 in the presence 
of CD16+ natural killer (NK) cells from human peripheral blood 
mononuclear cells (PBMCs) (54).
In another approach, Strop et  al. (55) developed bispecific 
IgG1 and IgG2 antibodies by oxidation/reduction methodology 
for chain pairing. They described bispecific mutations (K409 and 
L368) in the CH3 domain, which allowed the development of 
bsIg either by coexpressing monomers bearing common light 
chains or by mixing the purified monomers under mild reducing 
conditions. Highest bispecificity was achieved by complementing 
K409/L368 with either IgG1-hinge or IgG2-hinge mutations (55). 
A CD3 × CD20 bsIg so generated showed in vitro cytotoxicity 
against mouse B-cell lymphoma in the presence of freshly iso-
lated mouse primary T cells. Further, the bsIg mediated a dose-
dependent lysis of target cells and also depleted CD20+ B cells 
in vivo by T-cell engagement (55).
A similar concept to generate IgG1 bispecific molecules was 
applied by Labrijn et al. (56). They incorporated a P228S hinge 
mutation which makes bonds more susceptible to cleavage under 
reducing conditions and additional mutations in separate human 
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IgG1-CH3 domains to promote Fab-arm exchange. Two mutated 
antibodies in IgG1 format (anti-EGFR and anti-CD20) were 
expressed separately and then mixed together in the presence of 
reducing agent, which resulted in 96% efficient Fab-arm exchange 
(Figure  1K) (56). The bispecific molecules so generated were 
stable at 5°C for over a period of 6 months and had comparable 
pharmacokinetics to their parent antibodies. A dual targeting 
CD3 × HER2 bispecific IgG1 was also constructed and showed 
a great enhancement in the T cell-mediated cytotoxicity against 
breast adenocarcinoma cells (AU565) in comparison to control 
antibody and in  vivo tumor growth inhibition in an adoptive 
transfer xenograft model of gastric carcinoma with freshly pre-
pared human PBMCs (56).
eLeCTROSTATiC OPTiMiZATiON
Gunasekaran et  al. (59) exploited charged pair based attrac-
tion/repulsion in different Fc chains in the scFv-Fc format 
(Figure  1L). They identified conserved oppositely charged 
residues in the CH3–CH3 domain interface (D356–K439′, 
E357–K370′, K392–D399′, and D399–K409′). Among these, 
the D399–K409′ pair is buried and contributes to CH3–CH3 
interaction. Mutations in these key residues (K409D–D399′K, 
K409D–D399′R, K409E–D399′K, and K409E–D399′R) favored 
greater than 90% heterodimer formation (59). The strategy was 
applied to generate a CD3 ×  TARTK bsAb and shown to kill 
U87-TARTK+ human glioma cell line by CD3 ligation in the 
presence of human PBMCs (59).
Similarly, Choi et al. (60) substituted conserved and charged 
amino acids from the core of the CH3 domain with hydrophobic 
residues to perturb the structural symmetry and designed long-
range electrostatic attraction at the edge of the CH3 domain to 
promote heterodimer formation. A “W–VT” CH3 mutant pair 
(K409W and D399′V/F405′T) and “ER” CH3 mutant pair (K360E 
and Q347′R) accounted for 77 and 53% heterodimer species, 
respectively. This was attributed to the disruption of electrostatic 
and hydrophobic interactions and increased steric hindrance due 
to the K409W–F405′T mutations (60). Further, the combination 
of W–VT and ER mutant increased heterodimer formation up 
to 91%, enhanced binding to FcRn and imparted parent-like 
thermal stability. The “ERW–VT” mutant was used to generate 
MET × VEGFR-2 bispecific scFv (bscFv)-Fc, which bound more 
strongly to HUVEC cells and inhibited cell growth and VEGF/
HGF-mediated ERK/AKT signaling. The MET × VEGFR-2 bsAb 
induced a twofold greater reduction in tumor volume in MKN45 
human gastric cancer xenograft models compared to parent 
antibodies (60).
Subsequently, Fc heterodimer mutants were isolated based on 
displayed (CH3A) or secreted (CH3B) yeast libraries from either 
W–VT mutant or wild-type Fc incorporating K370–E357′/S364′ 
or D399–K392′/K409′ interaction pairs. The haploid yeast cells 
carrying individual libraries upon mating resulted in a diploid 
cell harboring both Fc variants, which if heterodimerized were 
displayed on the cell surface (61). In addition, these Fc variants 
carried C228S/C231S mutations to prevent homodimer forma-
tion and N297Q to avoid hypermannosylation in yeast (61).
Further, structure-guided design assisted with the computa-
tional algorithm and optimized energy function in between the 
partner chains were used to improve biophysical properties of 
bsIg molecules. Identified mutations [ZW1—Chain A (T350V/
L351Y/F405A/Y407V) and Chain B (T350V/T366L/K393L/
T394W)], which favor pure heterodimer formation (95%) and 
stability comparable to the wild-type Fc, were applied to create 
bispecific molecules (62). These mutations greatly improved the 
stability of the heterodimer when exposed to heat, acid, base, 
agitation, oxidation, freeze-thaw, and varying pH (62).
Electrostatic interactions were also optimized for the correct 
pairing of the heavy chain and its cognate light chain when 
coexpressed in the same cell. To achieve this, structure-guided 
mutations were made by replacing polar or hydrophobic residues 
of the CH1–CL and VH–VL interfaces with charged amino acids. 
These mutations promoted correct pairing of the heavy and light 
chains due to the maximization of electrostatic interactions over 
H-bonding and Van der Waals forces. The HER2 × EGFR bsIg 
induced a greater receptor internalization than achieved by the 
combination of parental antibodies and, furthermore, exhibited 
enhanced capability to inhibit BXPC-3, PANC-1, and Calu-3 
tumors in xenograft models (57).
CONCePTUAL ADvANCeS
Davis et al. (85) exploited the sequence diversity in CH3 domains 
of IgG and IgA (~47% diverse in humans) and proposed that if 
diverse patches of IgG and IgA CH3 domains are mutually replaced 
then they can be heterodimerized (85). This strategy resulted in 
a unique complementarity among the CH3–CH3 interface. It 
was experimentally shown by constructing a strand-exchange 
engineered domain body (SEEDbody) fusion protein [IgG1-
hinge-CH2-(SEED-IgA-CH3)], which preferentially associated 
into heterodimers (85–95%) (85). Depending on the patched 
sequence, these molecules were referred to as either AG or GA 
SEED. Further, novel SEEDbodies (Figure 1M) retained normal 
FcRn and protein A binding due to a specific motif introduced 
from IgG into the IgA. The major advantage of SEEDbody is to 
engineer additional specificity via scFv fused to the N-terminus of 
the SEEDbody, which overcomes the faulty light chain pairing (85).
Antibody scaffolds have also been used to develop bispecific 
pharmacophore fusions “COVX-Bodies” by chemical optimiza-
tion of bsAbs (86). The principle involved here is to chemically 
link two pharmacophore peptides via branched azetidinone 
linker followed by an irreversible site-specific covalent fusion to 
the scaffold antibody. The azetidinone linker interacts with the 
K94 of Ig heavy chain and establishes an amide bond with the 
antibody. For example, a humanized IgG1κ aldolase antibody 
has been used as a scaffold for monovalent display of anti-VEGF 
and anti-Ang2 peptide pharmacophores to develop a monovalent 
bispecific COVX-241 (86). The bispecific COVX-241 inhibited 
VEGF–VEGFR2/Ang2–Tie2 interactions and further exhibited 
an improved efficacy against colon adenocarcinoma xenograft 
model as compared to the monospecific COVX-body (86).
Another methodology to develop bsAbs was proposed by 
Wranik et  al. (87), which employed a common light chain 
and leucine zipper (LUZ-Y) (Figure  1N). They demonstrated 
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heterodimer assembly by creating a point mutation and the addi-
tion of a leucine zipper at the heavy chain C-terminus (87). Further, 
K222A substitution was made in the hinge region to avoid Lys-C 
endopeptidase-mediated cleavage if used for removing leucine 
zipper through C-terminal lysine of the CH3 domain. The light 
chain (VL–CL) was fused to the N-terminus of the heavy chain 
construct by a non-cleavable linker. However, the leucine zipper 
did not completely prevent homodimer formation, as an outcome 
of disproportionate expression in CHO cells most probably due 
to an incorrect DNA ratio during the transfection (87). Two 
armed LUZ-Y bispecific molecules hFcεRIα × hFcγRIIb showed 
desirable binding to respective targets and inhibited histamine 
release from hFcεRIα/hFcγRIIb+ rat basophil leukemia cells 
when activated by IgE. Similarly, EGFR × HER3 bispecific LUZ-Y 
inhibited the growth of EGFR/HER3-dependent FaDu cells (87).
Bispecific IgG has also been assembled from a bacterial expres-
sion system. Half-IgG (one heavy and one light chain) molecule 
representing MET (hole mutant) and EGFR (knob mutant) 
specificities were expressed in bacterial cultures separately. The 
half-IgGs were purified by protein A affinity chromatography and 
analyzed to quantify monomeric form by size exclusion chroma-
tography. Two half-IgGs were mixed in the presence of a reducing 
agent and subsequently oxidized to generate bsAb, which binds 
to the targets in a monovalent fashion (88). Similarly, a bacte-
rial coculture of two strains expressing individual half-IgGs was 
shown to be the most rapid and efficient way to produce bsAbs 
(88). These bsAb molecules also inhibited MET × EGFR driven 
tumor growth (88).
In another effort, broadly neutralizing anti-HA1 (Ab-002) 
and HA2 (Ab-005) antibodies against influenza virus A were 
covalently linked by their C-termini. This methodology involved 
the fusion of a bacterial sortase recognition motif (LPETGG) 
via G4S linker to the C-terminus of the IgG heavy chain. Click 
chemistry in the form of either cyclooctyne (DIBAC) or azide was 
used in the presence of sortase to promote covalent association of 
the two antibody molecules (89). Such covalently linked antibod-
ies remained stable for up to 3 weeks at 37°C and also retained 
the Fc effector functions. These bispecific covalently linked IgGs 
contributed to an increased breadth of HA binding and antiviral 
potency as compared to the monospecific molecules (89).
Further, the light chain pairing was also used to generate 
bsIg molecules (κλ-bodies) (Figure  1O). This was achieved by 
coexpressing a single heavy chain with two light chains (κ and λ) 
through a single expression vector (63). It was presumed that 50% 
yield would be of κλ heterodimers. The strategy involved a three-
step purification to separate (a) whole IgG fraction by protein A/
CH1 resin, (b) κ light chain by kappa select resin, and (c) λ light 
chain by lambda select resin. Fed-batch culture yielded 1.5 g/L of 
total IgG with 41% being κλ heterodimer (63).
Smith et  al. (58) used antibody isotype local chimeras to 
develop a bsAb that could trigger T cell-mediated B-cell killing. 
The rationale behind this approach was to exploit the differential 
protein A binding ability of antibody isotypes. It is known that 
IgG3 does not bind protein A and harbors a dipeptide Arg-Phe 
at the CH3 domain that corresponds to IgG1 H435 and Y436, 
respectively, while IgG1 can bind protein A with high affinity. 
Moreover, crystal structure of IgG1 in complex with protein A 
confirms that H435 is involved in interaction with protein A 
(90). Fc substitutions (H435R, Y436F) were created in anti-CD3 
antibody to develop CD3 × CD20 bsAb using a common light 
chain. Such isotype local chimeras exhibited asymmetric binding 
to protein A, which was exploited for separation of heterodimers 
by a pH gradient (58). The yield of the bispecific CD3 × CD20 
IgG1 (REGN2280) was 43%. The IgG4 isotype of CD3 × CD20 
(REGN1979) exhibited T cell-mediated cytotoxicity against 
CD20+ Raji lymphoma and inhibited the growth of Raji lym-
phoma cells in NOD SCIDγ (NSG) mice when injected along 
with the human PBMCs (58).
bsAb FRAGMeNTS FOR T CeLL  
AND NK CeLL ACTivATiON
Besides the different formats of full-length bsAb design, sig-
nificant effort has also been invested on bsAb fragment designs 
that lack Fc region or only contain some constant domains. The 
building blocks of bsAb fragments include nanobodies, human 
single-domain antibodies, scFvs, and Fabs (18). More than 25 
bsAb fragment formats have been documented, and most formats 
currently under clinical trial for treatment of different tumors 
involve bridging immune effector T cell (CD3 as the antigen) 
toward tumor specific antigens (18).
Blinatumomab, the first bsAb fragment and second bispecific 
molecule approved for therapy, is a bispecific T-cell engager 
(BiTE) molecule (Figure 1P; Table 2 for clinical status) that is 
built from two scFvs linked in tandem with a short peptide linker 
(64, 91). Blinatumomab uses one arm to recognize CD19, which 
is highly expressed on B-cell acute lymphocytic leukemia (ALL), 
and the other arm to recruit CD3, which is expressed on T cells, 
and induces a T-cell–tumor cell contact and potent lysis of tumor 
cell (64, 91, 92). Interestingly, the BiTE format of CD3 × CD19 
bispecific antibody is superior to other formats including diabody 
(66) (Figure 1Q), tandem diabody (Tandab) (67, 68) (Figure 1R) 
and quadroma in terms of T cell-mediated tumor cell lysis (93). 
This finding highlights that the relative orientation and distance 
between the two scFvs may have significant impacts on how to 
bridge T cell and tumor cell into close contact so as to trigger 
T cell-mediated tumor cell lysis. Currently, several bispecific 
antibody fragments based on BiTE, Tandab, and dual-affinity-
retargeting (Figure  1S) (69) formats are under clinical trials 
involving CD3 and tumor related antigens (18, 94) (Table 2).
Effects of bsAb fragments capable of interacting with NK cells 
via CD16 have also been investigated. Gleason and coworkers 
demonstrated the enhanced efficacy of bscFv CD16 × CD19 and 
trispecific scFv CD16 × CD19 × CD22 constructs in targeting 
tumor cells by coengaging NK cell effector function (70). These 
molecules were termed as bispecific and trispecific killer cell 
engagers (BiKEs and TriKEs) (Figures 1T,U), respectively. Such 
molecules are constructed by linking specific binders together 
through a short linker derived from human muscle aldolase. 
Further, a BiKE construct against CD16 and CD33 has been 
shown to activate CD16+ NK cells to lyse CD33+ HL60 target 
cells (71). Recently, a TriKE construct with additional specificity 
against IL-15 induced enhanced NK cell cytotoxicity, degranula-
tion, and cytokine production against CD33+ HL60 cells via 
10
Liu et al. Bispecific Antibodies and Novel Scaffolds
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 38
increased NK cell proliferation and survival (72). Reusch et al. 
designed a Tandab-based anti-CD16A × CD30 bispecific tetrava-
lent fragment and found that this format is better than normal 
monoclonal anti-CD30 IgG, optimized monoclonal anti-CD30 
IgG for FcγR binding, and diabody (bispecific and bivalent anti-
CD16A and anti-CD30) formats in triggering NK cell lysis of 
Hodgkin lymphoma cells (CD30 as the antigen) (95, 96). This 
format of anti-CD16A ×  CD30 bispecific fragment (known as 
AFM13) is under phase-2 clinical trial (Table 2) for treatment of 
refractory or relapsed Hodgkin lymphoma patients (97).
MONOMeRiC ig SCAFFOLDS
Much work in the last 5 years has focused on engineering the IgG 
constant domains as scaffolds. The IgG-Fc region and isolated CH 
domains have shown promising virtues in terms of small size, 
antigen targeting, effector function, and serum half-life.
Soluble monomeric Fc (mFc) was developed by destabilizing 
the CH3–CH3 domain interface. A phage-displayed library was 
constructed with random mutations introduced within seven key 
residues known to be involved in CH3 domain homodimeriza-
tion and selected against binding of protein G first to enrich 
well-folded mutants and then against human FcRn (16). The 
selected clones were diverse in their CH3 domain, and monomer 
promoting mutations were identified (16). These variants with 
each containing six to seven mutations had considerably lower 
melting temperature but exhibited comparable stabilities and pH-
dependent FcRn binding profiles to that of dimeric Fc (16). The 
experimental conceptualization was proved by mFc67.3–m36VH 
fusion (Figure 1V) targeting HIV-1 envelope glycoprotein (ENV) 
and neutralization of viral isolates (16). Based on the identified 
mFc mutants, the same group (98) optimized mFc to generate 
mutants with fewer mutations and improved thermostability 
while maintaining similar pH-dependent FcRn binding as that 
of wild-type Fc dimer. Interestingly, the new mFc mutants when 
expressed either in bacteria or mammalian cells all showed 
selective binding to only FcγRI but not to other receptors includ-
ing FcγRIIa, FcγRIIb, FcγRIIIa, and C1q (98). This selectivity 
attractively made the mFc mutant as a potential carrier to treat 
chronic inflammatory diseases where inflammatory macrophages 
showed increased expression of FcγRI (98–103). In addition, this 
selectivity also excluded unwanted cytotoxicities such as ADCC 
from FcγRIIIa and CDC from C1q (98).
In another strategy to keep Fc in a monomeric form, aspara-
gine-linked glycan structures were engineered into the CH3–CH3 
interface of IgG1 Fc lacking the hinge (104). A mutant incorpo-
rating N-glycosylation sites (asparagine at positions 364 and 407) 
yielded a stable, soluble, and mFc scaffold with wild-type-like 
FcRn binding activity, which suggests that N-glycosylation pro-
motes functional monomeric state and improves the biophysical 
characteristics (104).
Smaller scaffolds like CH2 domains also possess interesting 
properties like a properly folded structure, conformational flex-
ibility, lesser propensity to dimerize, and associated FcRn/C1q 
binding functions, which can have therapeutic benefits (103, 105). 
A CH2 domain variant (m01) harboring disulfide bond muta-
tions (L12C and K104C) was found to exist solely as a monomer 
and remained thermally more stable than native counterparts 
(105). Further, 50% of monomeric CH2 unfolded at a urea 
concentration of 6.8 M as compared to 4.8 M for the wild-type 
CH2 (105). The biophysical attributes of the CH2 domain (m01) 
were further optimized by developing a shorter version where 
the unstructured random coil at the N-terminus was shortened 
by seven residues (m01s) (106). This strategy increased the melt-
ing temperature of CH2 isolate up to 82.6°C, enhanced stability 
in serum and mediated stronger binding to soluble FcRn (106). 
Similarly, a structure-guided design allowed the engineering of 
an IgG1-CH3 FcRn recognition motif into the CH2 scaffold to 
impart enhanced pH-dependent FcRn binding, prolongation 
of serum half-life, and epithelial transcytosis in comparison to 
parent CH2 isolate (m01s) (107).
Antigen recognition activity was engineered in CH2 scaffolds 
carrying mutations in the BC and FG loops by selecting against 
the HIV-1 envelope glycoprotein (gp120)–CD4 complex (15), 
which yielded CH2 fragments bearing the same BC but differ-
ent FG loops, suggesting the importance of the latter in such 
interactions. One such isolate (m1a1) specifically recognized a 
highly conserved CD4i epitope on the HIV-1 gp120 protein and 
neutralized HIV-1 isolates in a cell based pseudovirus assay (15). 
In another approach, a randomly selected VH domain targeting 
the HIV-1 gp41 protein was grafted into the BC/FG loops of 
“m01s” without affecting the flanking regions to develop antigen 
targeting CH2 domains (m2a1) (108). This domain bound to 
sp62 peptide of HIV-1 envelope membrane-proximal external 
region, neutralized HIV-1 isolates, and showed pH-dependent 
FcRn interaction (108).
Initial success with the mFc and CH2 domains prompted the 
development of a monomeric CH3 (mCH3) scaffold (103, 109). 
The seven contact residues of the CH3 domain from the previ-
ously reported mFc molecules (16) were mutated, and a combina-
tion of mutations was found to be required for CH3 monomer 
to exist (109). These mutations were responsible for stronger 
intermolecular hydrophobic interactions, which resulted in an 
intact, folded and thermally stable CH3 monomer (109). The 
mCH3 scaffold exhibited significant binding to FcRn and protein 
G (109). Furthermore, mCH3 fused to a VH domain of an HIV-1 
targeting antibody (m36.4) showed satisfactory stability, viral 
neutralization, and pH-dependent FcRn binding (109). A com-
parative analysis between the dimeric and monomeric scaffolds 
has demonstrated increased solubility, comparable serum stabil-
ity, and higher pH-dependent FcRn binding by monomers (103). 
These properties make antibody scaffolds promising potential 
therapeutic candidates.
Fc ANTiGeN-BiNDiNG FRAGMeNT
The Fc has also been developed as an antigen-binding domain 
“Fcab” (Figure  1W) by imparting specificity against antigens 
through yeast surface display (110). The AB and EF loops of 
IgG1-CH3 domain were randomly mutagenized, cloned into 
a yeast surface display vector, and selected against HER2/neu 
extracellular domain (ECD) for two rounds. The selected binders 
were again randomized in the AB loop and selected on HER2/
neu ECD. One of the isolated Fcab molecules (H10-03-6) showed 
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specificity for binding to HER2, retained binding to FcγRI/protein 
A, and exhibited an in vivo pharmacokinetics profile similar to 
the native human Fc (110). Post-affinity maturation, Fcab exhib-
ited ~10-fold enhanced binding to the antigen as compared to 
the parental molecule and elicited NK cell-mediated cytotoxicity 
in vitro against the breast cancer cell line Calu-3, but the potency 
was ~20-fold weaker than that of Herceptin (110).
Introducing antigen-binding ability into the Fc fragment 
could compromise stability, and therefore, additional disulfide 
bonds were engineered within the CH3 domain to provide 
increased stability (111). Further, these mutations did not affect 
pH-dependent FcRn binding, which suggests the correct fold-
ing of the engineered Fc fragments (111). Similarly, immune 
modulating activity of Fcab was demonstrated using a HER2 
targeting Fcab (HAF3–4), bearing CD16a modulating mutations 
(111). Both mutants showed binding to the recombinant or cell 
surface expressed HER2 and had an expected CD16a modulating 
behavior which correlated with the ADCC potency (111). Later, 
Woisetschlager and coworkers (112) showed the in vivo tumor 
reduction efficacy of anti-HER2 Fcab (H10-03-6) by simultane-
ous engagement of the HER2/CD16a and the involvement of 
ADCC (112).
Since antigen–antibody interaction at an acidic pH can nega-
tively affect drug pharmacokinetics, anti-HER2 Fcab (H10-03-6) 
variants with weaker binding at pH 6.0 were developed (113). 
The residues in the AB and EF loops were randomized and 
selected against HER2-ECD alternately at pH 7.4 and 6.0 using 
yeast display. The isolated binders exhibited lower affinity at an 
acidic pH and similarly engaged HER2+ cells in a pH-dependant 
manner (113). A year later, Leung et al. (114) developed Fcab that 
could degrade HER2 and induce apoptosis. The AB and EF loop 
residues of IgG-Fc were randomly mutagenized and selected via 
yeast display for binding to HER2-ECD. After affinity maturation, 
the candidate Fcab (FS102) exhibited an affinity for HER2-ECD 
that was equivalent to that of pertuzumab and trastuzumab and 
an extended serum half-life comparable to the native Fc (114). 
Further, EC50 values of 1.1 and 3.3  nM were observed against 
SKBr3 and HCC1954 breast cancer cells, respectively, and a com-
plete tumor regression was shown using HER2+ patient-derived 
colorectal/gastric cancer xenografts (114). This effect correlated 
with caspase 3/7 activation in SKBr3 cells in a dose-dependent 
manner indicating the induction of tumor cell apoptosis (114).
CHALLeNGeS iN CLiNiCAL 
DeveLOPMeNT OF bsAbs AND 
FRAGMeNTS
Smaller antibody fragments (nanobody, human single-domain 
Ab, scFv, or Fab) and bsAb fragments offer a number of advan-
tages over full-length IgG, including ability to penetrate tissue, 
cost effective and facile manufacturing methods, and high yields 
(23, 115). However, their small size leads to a shorter serum half-
life, lesser tissue retention, and rapid clearance from the blood 
through kidneys. This is true for blinatumomab, which has a 
serum half-life of around 2 h while the serum half-life of full-
length IgG1 is around 2–3 weeks. Thus, patients need a regimen 
of at least 3-cycle treatment with each cycle consisting of continu-
ous infusion for 4 weeks in a cycle of 6 weeks (116). On the other 
hand, the fast clearance of small size bsAb fragments may be 
desirable in imaging and radioimmunotherapy (117, 118).
Specific approaches can be used to increase the longevity of 
small bsAb fragments in blood and tissue by (1) fusion of the Fc 
region of IgG molecules or human serum albumin to prolong the 
serum half-life. These fusions not only increase molecular size of 
bsAb fragments and therefore protect them from being excreted 
out of the body but also mediate binding to the FcRn expressed 
on the endothelial cells to enter IgG serum stabilization pathway 
(25, 119–121); (2) multimerization of antibody fragments to 
increase the molecular size for stabilizing concentration in blood 
and enhancing the valency of antigen binding (120, 122). The 
multimerization approach, however, runs a risk of imparting 
heterogeneity to the molecule and can also lead to undesirable 
effects by crosslinking of the target receptor (120); and (3) linking 
of a hydrophobic molecule like polyethylene glycol, a clinically 
proven technology for serum half-life extension (120, 123). 
Besides, other polymers like polysialic acid, N-(2-hydroxypropyl) 
methacrylamide, and dextran can also provide protection to the 
small antibody fragments (25, 120).
Currently, there are more than 60 bsAb formats (18). Of note, 
the success story of blinatumomab in the format of BiTE, but 
not in other formats including diabody, Tandab, and quadroma 
indicates that bispecific molecule design has to consider more 
than one format from the beginning (93). Moreover, expression 
and purification of these variable formats require tailored pro-
cedures based on each design. This may pose a great challenge 
in developing bispecific molecules. Table 1 summarizes relevant 
information from available literatures.
FiNAL ReMARKS
Considerable progress has been made in the development of 
bispecific molecules based on different scaffolds in recent years. 
Much of this understanding has made it possible to enter an 
era of bispecific clinical development with two such molecules 
(catumaxomab and blinatumomab) having been approved for 
clinical use in humans (18). The field of bsAbs has been evolution-
ary and revolutionary, which is reflected in our ability to obtain 
100% pure heterodimers, the complete evasion of heavy and light 
chain mispairing, fairly standardized production/purification/
analytical methods and, importantly, clear ideas of their potential 
applications.
The full-length mAbs have relatively poor tissue penetration 
ability. In contrast, smaller antibody fragments like BiTE, BiKE, 
and TriKE can effectively penetrate tumor tissue and efficiently 
recruit and activate immune effector cells to lyse tumor cells 
(23, 70, 93, 115). Besides, the recent success in delivering a bsIg 
across the blood–brain barrier by targeting transferrin receptor 
and β-secretase to reduce brain amyloid-β in non-human primate 
model may open the era of specific antibody brain delivery 
and treatment of neurodegenerative diseases (124). In another 
possibility, combining non-antibody small fragments such as 
lambody, affibody, and aptamer with current antibody scaffolds 
may expand the treatment arsenal of bispecific molecules.
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